Paysign raises FY25 revenue view to $76.5M-$78.5M ffrom $72M-$74M

Consensus $75.15M. “With the results of our second quarter of 2025 now in the books, the new plasma centers coming into the mix, and the strong pipeline we have in our pharma patient affordability business, we are revising our full-year 2025 estimated results upward. We expect total revenues to be in the range of $76.5 million to $78.5 million, reflecting year-over-year growth of 32.7% at the midpoint. Plasma is estimated to make up approximately 56% of total revenue, representing flat year-over-year growth, while pharma patient affordability revenue is expected to make up approximately 40.5% of total revenue, representing year-over-year growth of over 145%. Despite the seasonality we typically see with our pharma patient affordability business and industry trends in our plasma business, we now forecast revenue to grow in the second half of the year compared to the first half of the year. Full-year gross profit margins are expected to be between 61.0% and 62.0% as we bring up the new patient services contact center in the third quarter to support the growth in our pharma patient affordability business. We continue to expect operating expenses to be between $41.0 million and $43.0 million with depreciation and amortization expense of approximately $8.4 million and stock-based compensation of approximately $4.4 million. Interest income is estimated to be approximately $2.5 million, reflecting the implied interest expense for future Gamma payments. Taking all the factors above into consideration, we continue to expect net income to be between $6.0 million and $7.0 million for the year, or $0.10 to $0.12 per diluted share, but that may fluctuate depending on our effective tax rate. The effective tax rate for the second quarter was 32.1% due to the impact of discrete items related to the appreciation of our stock price. Adjusted EBITDA is expected to be in the range of $18.0 million to $20.0 million, or $0.31 to $0.35 per diluted share. The diluted share count for the year is estimated to be 57.5 million shares due to options being in the money.”